Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

Circulation

Volumn 110, Issue 8, 2004, Pages 921-927

  De Zeeuw, Dick ^a   Remuzzi, Giuseppe ^b   Parving, Hans Henrik ^c   Keane, William F ^d   Zhang, Zhongxin ^d   Shahinfar, Shahnaz ^d   Snapinn, Steve ^d   Cooper, Mark E ^e   Mitch, William E ^f   Brenner, Barry M ^g  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

^c AARHUS UNIVERSITY   (Denmark)

^d MERCK RESEARCH LABORATORIES   (United States)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Albuminuria; Angiotensin; Cardiovascular disease; Diabetes; Proteinuria

Indexed keywords

ANGIOTENSIN II ANTAGONIST; LOSARTAN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; HEART FAILURE; HEART PROTECTION; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT;

AGED; ALBUMINURIA; ANGINA, UNSTABLE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; LIFE TABLES; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 4344621497     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000139860.33974.28     Document Type: Article

References (29)

1. King H, Aubert R, Herman W. Global burden of diabetes 1995-2025: prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414-1431.
2. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14(S 5):S1-S85.
3. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(suppl 2):S14-S21.
4. Parving H-H. Diabetic nephropathy: prevention and treatment. Kidney Int. 2001;60:2041-2055.
5. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346:1145-1151.
6. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003;26(suppl 1):S83-S86.
7. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
9. Rossing P, Hougaard P, Borch-Johnsen K, et al. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ. 1996;313:779-784.
10. Wang SL, Head J, Stevens L, et al. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization Multinational Study of Vascular Disease in Diabetes. Diabetes Care. 1996;19:305-312.
11. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int. 2003;63:1499-1507.
12. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
13. Apperloo AJ, De Zeeuw D, De Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994;45(suppl 45): S174-S178.
14. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
15. Brenner BM, Cooper MA, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
16. Brenner BM, Cooper ME, de Zeeuw D, et al. The Losartan Renal Protection Study: rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst. 2000;1:328-335.
17. Kannel WB, Stampfer MJ, Castelli WP. The prognostic significance of proteinuria: the Framingham study. Am Heart J. 1984;108:1347-1352.
18. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32:219-226.
19. Samuelsson O, Wilhelmsen L, Pennert K, et al. Prognostic factors in treated hypertension. J Hypertens. 1985;3(suppl 3):S497-S500.
20. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
21. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
22. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
23. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
24. El Nahas AM, Masters-Thomas A, Brady SA, et al. Selective effect of low protein diets in chronic renal diseases. BMJ. 1984;289:1337-1341.
25. Vriesendorp R, Donker AJM, de Zeeuw D, et al. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med. 1986;81(suppl 2B): 84-94.
26. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963-1974.
27. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861-867.
28. Laverman GD, Henning RH, De Jong PE, et al. Optimal antiproteinuric dose of losartan in non-diabetic patients with nephrotic range proteinuria. Am J Kidney Dis. 2001;38:1381-1384.
29. Andersen S, Rossing P, Juhl TR, et al. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transpl. 2002;17:1413-1418.